Nanobead-based interventions for the treatment and prevention of tuberculosis

Nature Reviews Microbiology

Volumn 8, Issue 11, 2010, Pages 827-834

  Griffiths, Gareth ^a   Nyström, Bo ^a   Sable, Suraj B ^b   Khuller, Gopal K ^c  

^a UNIVERSITY OF OSLO   (Norway)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CAPREOMYCIN; ECONAZOLE; ISONIAZID; MOXIFLOXACIN; NANOBEAD; POLYGLACTIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC THERAPY; BACTERICIDAL ACTIVITY; BCG VACCINATION; CYTOLOGY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TUBERCULOSIS;

ADULT; ANIMALS; ANTITUBERCULAR AGENTS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; NANOCAPSULES; NANOPARTICLES; NANOSPHERES; NANOTECHNOLOGY; TUBERCULOSIS VACCINES; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

BACTERIA (MICROORGANISMS); MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS;

EID: 77958100679     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro2437     Document Type: Review

References (70)

1. Young, D., Perkins, M., Duncan, K. & Barry, C. E. 3rd. Confronting the scientific obstacles to global control of tuberculosis. J. Clin. Invest 118, 1255-1265 (2008).
2. Dye, C. & Williams, B. G. The population dynamics and control of tuberculosis. Science 328, 856-861 (2010).
3. Russell, D. G., Barry, C. E. 3rd & Flynn, J. L Tuberculosis: what we don't know can, and does, hurt us. Science 328, 852-856 (2010).
4. Chan, E. D. & Iseman, M. D. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr. Opin. Infect. Dis. 21, 587-595 (2008).
5. Zhang, Y. & Yew, W. W. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 13, 1320-1330 (2009).
6. Dye, C. Doomsday postponed? Preventing and reversing epidemics of drug-resistant tuberculosis. Nature Rev. Microbiol. 7, 81-87 (2009).
7. Bhatt, K. & Salgame, P. Host innate immune response to Mycobacterium tuberculosis. J. Clin. Immunol. 27, 347-362 (2007).
8. Vergne, I., Chua, J., Singh, S. B. & Deretic, V. Cell biology of Mycobacterium tuberculosis phagosome. Annu. Rev. Cell Dev. Biol. 20, 367-394 (2004).
9. Cooper, A. M. Cell-mediated immune responses in tuberculosis. Annu. Rev. Immunol. 27, 393-422 (2009).
10. Couvreur, P. & Vauthier, C. Nanotechnology: intelligent design to treat complex disease. Pharm. Res. 23, 1417-1450 (2006).
11. Zhang, L. et al. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 83, 761-769 (2008).
12. Davis, M. E., Chen, Z. G. & Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Rev. Drug Discov. 7, 771-782 (2008).
13. Sosnik, A., Carcaboso, A. M., Glisoni, R. J., Moretton, M. A. & Chiappetta, D. A. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Ad v. Drug Deliv. Rev. 62, 547-559 (2010).
14. Khuller, G. K., Kapur, M. & Sharma, S. Liposome technology for drug delivery against mycobacterial infections. Curr. Pharm. Des 10, 3263-3274 (2004).
15. Pandey, R. & Khuller, G. K. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 85, 227-234 (2005).
16. Desjardins, M. & Griffiths, G. Phagocytosis: latex leads the way. Curr. Opin. Cell Biol. 15, 498-503 (2003).
17. Areschoug, T. & Gordon, S. Scavenger receptors: role in innate immunity and microbial pathogenesis. Cell. Microbiol. 11, 1160-1169 (2009).
18. Yoshida, A. et al. Selective delivery of rifampicin incorporated into poly(D?-lactic-co-glycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette-Guérin. Microbes Infect 8, 2481-2491 (2006).
19. Hirota, K. et al. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J. Control. Release 142, 339-346 (2010).
20. Kisich, K. O. et al. Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis. Int. J. Pharm. 345, 154-162 (2007).
21. Onoshita, T. et al. The behavior of PLGA microspheres containing rifampicin in alveolar macrophages. Colloids Surf. B Biointerfaces 76, 151-157 (2010).
22. Pandey, R. & Khuller, G. K. Polymer based drug delivery systems for mycobacterial infections. Curr. Drug Deliv. 1, 195-201 (2004).
23. Shive, M. S. & Anderson, J. M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28, 5-24 (1997).
24. Anisimova, Y V., Gelperina, S. I., Peloquin, C. A. & Heifets, L. B. Nanoparticles as antituberculosis drugs carriers: effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages. J. Nanopart. Res. 2, 165-171 (2000).
25. Muttil, P. et al. Inhalable microparticles containing large payload of anti-tuberculosis drugs. Eur. J. Pharm. Sci. 32, 140-150 (2007).
26. Singh, R. & Li llard, J. W. Jr. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol. 86. 215-223 (2009).
27. Sharma, A., Sharma, S. & Khuller, G. K. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J. Antimicrob. Chemother. 54, 761-766 (2004).
28. Pandey, R. et al. Poly (D?-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J. Antimicrob. Chemother. 52, 981-986 (2003).
29. Garcia-Contreras, L. et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob. Agents Chemother. 51, 2830-2836 (2007).
30. Ahmad, Z., Sharma, S. & Khuller, G. K. The potential of azole antifungals against latent/persistent tuberculosis. FEMS Microbiol. Lett 258, 200-203 (2006).
31. Pandey, R. & Khuller, G. K. Nanoparticle-based oral drug delivery system for an injectable antibiotic-streptomycin. Evaluation in a murine tuberculosis model. Chemotherapy 53, 437-441 (2007).
32. Hussain, N., Jaitley, V. & Florence, A. T Recent advances in the understanding of uptake of microparticulates across the gastrointestinal lymphatics. Adv. Drug Deliv. Rev. 50, 107-142 (2001).
33. Ahmad, Z. & Khuller, G. K. Alginate-based sustained release drug delivery systems for tuberculosis. Expert Opin. Drug Deliv. 5, 1323-1334 (2008).
34. Jain, R. A. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 21, 2475-2490 (2000).
35. Gaumet, M., Gurny, R. & Delie, F. Localization and quantification of biodegradable particles in an intestinal cell model: the influence of particle size. Eur. J. Pharm. Sci. 36, 465-473 (2009).
36. Skeiky, Y. A. & Sadoff, J. C. Advances in tuberculosis vaccine strategies. Nature Rev. Microbiol. 4, 469-476 (2006).
37. Andersen, P. Vaccine strategies against latent tuberculosis infection. Trends Microbiol. 15, 7-13 (2007).
38. Fifis, T. et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173, 3148-3154 (2004).
39. Xiang, S. D. et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods 40, 1-9 (2006).
40. Hu, Y. et al. Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. Nano Lett 7, 3056-3064 (2007).
41. Verma, A. et al. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nature Mater. 7, 588-595 (2008).
42. Dhiman, N. & Khuller, G. K. Protective efficacy of mycobacterial 71-kDa cell wall associated protein using poly (D?-lactide-co-glycolide) microparticles as carrier vehicles. FEMS Immunol. Med. Microbiol. 21, 19-28 (1998).
43. Venkataprasad, N. et al. Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers. Vaccine 17, 1814-1819 (1999).
44. Carpenter, Z. K., Williamson, E. D. & Eyles, J. E. Mucosal delivery of microparticle encapsulated ESAT-6 induces robust cell-mediated responses in the lung milieu. J. Control. Release 104, 67-77 (2005).
45. Kirby, D. J. et al. PLGA microspheres for the delivery of a novel subunit TB vaccine. J. Drug Target 16, 282-293 (2008).
46. Shi, S. & Hickey, A. J. PLGA microparticles in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen TB10.4-Ag85B. Pharm. Res. 27, 350-360 (2010).
47. Lu, D. et al. Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity. AAPS J. 12, 338-347 (2010).
48. Muttil, P., Wang, C. & Hickey, A. J. Inhaled drug delivery for tuberculosis therapy. Pharm. Res. 26, 2401-2416 (2009).
49. Mollenkopf, H. J. et al. Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine 22, 2690-2695 (2004).
50. Johansen, P. et al. Anti-mycobacterial immunity induced by a single injection of M. leprae Hsp65-encoding plasmid DNA in biodegradable microparticles. Immunol. Lett. 90, 81-85 (2003).
51. Bivas-Benita, M. et al. Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201- restricted T-cell epitopes of Mycobacterium tuberculosis. Vaccine 22, 1609-1615 (2004).
52. Bivas-Benita, M. et al. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine 27, 4010-4017 (2009).
53. Akin, D. et al. Bacteria-mediated delivery of nanoparticles and cargo into cells. Nature Nanotech. 2, 441-449 (2007).
54. Cosma, C. L., Humbert, O., Sherman, D. R. & Ramakrishnan, L. Trafficking of superinfecting Mycobacterium organisms into established granulomas occurs in mammals and is independent of the Erp and ESX-1 mycobacterial virulence loci. J. Infect Dis. 198, 1851-1855 (2008).
55. Garcia-Contreras, L. et al. Immunization by a bacterial aerosol. Proc. Natl Acad. Sci. USA 105, 4656-4660 (2008).
56. H 1 response in BALB/c mice. Vaccine 25, 4595-4601 (2007).
57. Wong, Y. L. et al. Drying a tuberculosis vaccine without freezing. Proc. Natl Acad. Sci. USA 104, 2591-2595 (2007).
58. Sung, J. C., Pulliam, B. L. & Edwards, D. A. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 25, 563-570 (2007).
59. Singh, R. & Kostarelos, K. Designer adenoviruses for nanomedicine and nanodiagnostics. Trends Biotechnol. 27, 220-229 (2009).
60. Reddy, S. T., Swartz, M. A. & Hubbell, J. A. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 27, 573-579 (2006).
61. Liu, P. T. et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311, 1770-1773 (2006).
62. Liu, P. T., Stenger, S., Tang, D. H. & Modlin, R. L. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J. Immunol. 179, 2060-2063 (2007).
63. Sharma, S., Verma, I. & Khuller, G. K. Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: in vitro and ex vivo study. Eur. Respir. J. 16, 112-117 (2000).
64. Toro, J. C. et al. Enhanced susceptibility of multidrug resistant strains of Mycobacterium tuberculosis to granulysin peptides correlates with a reduced fitness phenotype. Microbes Infect 8, 1985-1993 (2006).
65. Bottger, E. C., Springer, B., Pletschette, M. & Sander, P. Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nature Med. 4, 1343-1344 (1998).
66. Amaral, L., Martins, M. & Viveiros, M. Phenothiazines as anti-multi-drug resistant tubercular agents. Infect. Disord. Drug Targets 7, 257-265 (2007).
67. Kuijl, C. et al. Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature 450, 725-730 (2007).
68. Lee, C. C., MacKay, J. A., Frechet, J. M. & Szoka, F C. Designing dendrimers for biological applications. Nature Biotechnol. 23, 1517-1526 (2005).
69. Kumar, P. V., Agashe, H., Dutta, T. & Jain, N. K. PEGylated dendritic architecture for development of a prolonged drug delivery system for an antitubercular drug. Curr. Drug Deliv. 4, 11-19 (2007).
70. Wolf, A. J. et al. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J. Exp. Med. 205, 105-115 (2008).